EA201000921A1 - Конъюгаты антител против rg-1 - Google Patents
Конъюгаты антител против rg-1Info
- Publication number
- EA201000921A1 EA201000921A1 EA201000921A EA201000921A EA201000921A1 EA 201000921 A1 EA201000921 A1 EA 201000921A1 EA 201000921 A EA201000921 A EA 201000921A EA 201000921 A EA201000921 A EA 201000921A EA 201000921 A1 EA201000921 A1 EA 201000921A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- conjugates antibodies
- conjugates
- partner
- cytotoxins
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99169007P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/084899 WO2009073524A2 (en) | 2007-11-30 | 2008-11-26 | Conjugates of anti-rg-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201000921A1 true EA201000921A1 (ru) | 2010-12-30 |
Family
ID=40427118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201000921A EA201000921A1 (ru) | 2007-11-30 | 2008-11-26 | Конъюгаты антител против rg-1 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110020329A1 (https=) |
| EP (1) | EP2211908A2 (https=) |
| JP (1) | JP2011505371A (https=) |
| KR (1) | KR20100101122A (https=) |
| CN (1) | CN101951960A (https=) |
| AR (1) | AR069746A1 (https=) |
| AU (1) | AU2008331507A1 (https=) |
| BR (1) | BRPI0819765A2 (https=) |
| CA (1) | CA2707443A1 (https=) |
| CL (1) | CL2008003525A1 (https=) |
| CO (1) | CO6210734A2 (https=) |
| EA (1) | EA201000921A1 (https=) |
| IL (1) | IL206060A0 (https=) |
| MX (1) | MX2010005683A (https=) |
| NZ (1) | NZ586514A (https=) |
| TW (1) | TW200930407A (https=) |
| WO (1) | WO2009073524A2 (https=) |
| ZA (1) | ZA201003729B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005263555B2 (en) * | 2004-07-16 | 2011-01-27 | Amgen Research (Munich) Gmbh | Expression-enhanced polypeptides |
| AU2009320481C1 (en) | 2008-11-03 | 2016-12-08 | Syntarga B.V. | Novel CC-1065 analogs and their conjugates |
| AU2011243294C1 (en) | 2010-04-21 | 2015-12-03 | Syntarga B.V. | Novel conjugates of CC-1065 analogs and bifunctional linkers |
| CN114805583A (zh) | 2010-05-27 | 2022-07-29 | 根马布股份公司 | 针对her2的单克隆抗体 |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| AU2015205574B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Method for purifying Cys-linked antibody-drug conjugates |
| JP2017510548A (ja) * | 2014-01-29 | 2017-04-13 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途 |
| IL316357A (en) * | 2017-07-31 | 2024-12-01 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978757A (en) * | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US5332837A (en) * | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) * | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) * | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| JP2510335B2 (ja) * | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) * | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| AU648313B2 (en) * | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2165819C (en) * | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
| JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5871969A (en) * | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US7129261B2 (en) * | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| CA2459308A1 (en) * | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| GT200400138A (es) * | 2003-07-22 | 2005-03-22 | Anticuerpos rgi y uso de los mismos. | |
| RU2402548C2 (ru) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| JP4806680B2 (ja) * | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| BRPI0617546A2 (pt) * | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| CA2627190A1 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| JP5189082B2 (ja) * | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
-
2008
- 2008-11-26 BR BRPI0819765 patent/BRPI0819765A2/pt not_active IP Right Cessation
- 2008-11-26 AU AU2008331507A patent/AU2008331507A1/en not_active Abandoned
- 2008-11-26 CA CA2707443A patent/CA2707443A1/en not_active Abandoned
- 2008-11-26 US US12/745,337 patent/US20110020329A1/en not_active Abandoned
- 2008-11-26 CL CL2008003525A patent/CL2008003525A1/es unknown
- 2008-11-26 NZ NZ586514A patent/NZ586514A/en not_active IP Right Cessation
- 2008-11-26 EP EP08858236A patent/EP2211908A2/en not_active Withdrawn
- 2008-11-26 WO PCT/US2008/084899 patent/WO2009073524A2/en not_active Ceased
- 2008-11-26 AR ARP080105135A patent/AR069746A1/es not_active Application Discontinuation
- 2008-11-26 EA EA201000921A patent/EA201000921A1/ru unknown
- 2008-11-26 KR KR1020107014394A patent/KR20100101122A/ko not_active Withdrawn
- 2008-11-26 TW TW097145816A patent/TW200930407A/zh unknown
- 2008-11-26 MX MX2010005683A patent/MX2010005683A/es not_active Application Discontinuation
- 2008-11-26 JP JP2010536173A patent/JP2011505371A/ja not_active Withdrawn
- 2008-11-26 CN CN2008801259196A patent/CN101951960A/zh active Pending
-
2010
- 2010-05-25 ZA ZA2010/03729A patent/ZA201003729B/en unknown
- 2010-05-28 CO CO10064681A patent/CO6210734A2/es not_active Application Discontinuation
- 2010-05-30 IL IL206060A patent/IL206060A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110020329A1 (en) | 2011-01-27 |
| KR20100101122A (ko) | 2010-09-16 |
| CA2707443A1 (en) | 2009-06-11 |
| MX2010005683A (es) | 2010-06-11 |
| JP2011505371A (ja) | 2011-02-24 |
| ZA201003729B (en) | 2011-08-31 |
| WO2009073524A2 (en) | 2009-06-11 |
| CN101951960A (zh) | 2011-01-19 |
| TW200930407A (en) | 2009-07-16 |
| AU2008331507A1 (en) | 2009-06-11 |
| AR069746A1 (es) | 2010-02-17 |
| CL2008003525A1 (es) | 2010-01-22 |
| WO2009073524A3 (en) | 2009-12-10 |
| NZ586514A (en) | 2012-05-25 |
| BRPI0819765A2 (pt) | 2015-05-05 |
| EP2211908A2 (en) | 2010-08-04 |
| IL206060A0 (en) | 2010-11-30 |
| CO6210734A2 (es) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000921A1 (ru) | Конъюгаты антител против rg-1 | |
| EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
| EA201000910A1 (ru) | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения | |
| MX2009006277A (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. | |
| EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
| EA201201533A1 (ru) | Prlr-специфическое антитело и его применения | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| UA111341C2 (uk) | Аматоксиновий кон'югат з покращеними лінкерами | |
| NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
| UA110370C2 (en) | Conjugates of amatoxin with improved linkages | |
| MX338754B (es) | Anticuerpos humanos contra el factor tisular. | |
| EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
| CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
| GEP20196956B (en) | Anti-gcc antibody molecules and related compositions and methods | |
| EA201270174A1 (ru) | Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина | |
| EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
| MX2009005776A (es) | Anticuerpos humanos que se enlazan al cd 22 y sus usos. | |
| MX2012003939A (es) | Fusiones y conjugados de farmaco. | |
| EA200900040A1 (ru) | Молекулы антител, которые связываются с человеческим il-17 | |
| EA200970954A1 (ru) | Пентаспецифические антитела, способы их получения и применения | |
| MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. | |
| EP2631248A3 (en) | Treatment of tumors using specific anti-L1 antibody | |
| UA105760C2 (uk) | Антитіло проти bst2 | |
| MY208842A (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof |